MeSH

A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family.

Year introduced: 1990

Date introduced: February 9, 1989

insulin with an additional lysine residue on the B-chain C-terminus

Date introduced: September 13, 2003

Date introduced: December 3, 1993

Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.

Year introduced: 2002

An aseptic, inflammatory arthritis developing secondary to a primary extra-articular infection, most typically of the GASTROINTESTINAL TRACT or UROGENITAL SYSTEM. The initiating trigger pathogens are usually SHIGELLA; SALMONELLA; YERSINIA; CAMPYLOBACTER; or CHLAMYDIA TRACHOMATIS. Reactive arthritis is strongly associated with HLA-B27 ANTIGEN.

Year introduced: 1992

A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.

Year introduced: 1990

Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.

Year introduced: 1989

a synthetic blood-brain barrier permeant peptide derived from calpastatin; amino acid sequence in first source

Date introduced: June 21, 2009

CD4 and CD8 T cells participate in the response to the rHSP60Kp in B27+ AS patients

Date introduced: March 22, 2006

protein from cell wall of Klebsiella K43-BTS1 that cross reacts with cells from HLA-B27 positive patients with ankylosing spondylitis

Date introduced: January 29, 1987

A spectrum of chronic inflammatory conditions affecting the axial joints (e.g., SPINE), characterized by pain, stiffness of joints (ANKYLOSIS), reduced mobility and inflammation. When joint inflammation and damage are visible on regular X-rays it is called ANKYLOSING SPONDYLITIS; otherwise it is referred to as NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. HLA-B27 ANTIGEN is a biomarker and IL-23/IL-17 pathway a potential therapeutic target for axial and other related spondyloarthritis.

Year introduced: 2022